This HTML5 document contains 97 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n18http://www.rxlist.com/cgi/generic3/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00305/identifier/chebi/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n8http://linked.opendata.cz/resource/AHFS/
n11http://linked.opendata.cz/resource/drugbank/company/
n17http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n29http://linked.opendata.cz/resource/drugbank/dosage/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00305/identifier/wikipedia/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00305/identifier/pharmgkb/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00305/identifier/kegg-compound/
n21http://bio2rdf.org/drugbank:
n22http://linked.opendata.cz/resource/drugbank/drug/DB00305/identifier/pubchem-compound/
admshttp://www.w3.org/ns/adms#
n23http://linked.opendata.cz/resource/drugbank/drug/DB00305/identifier/pubchem-substance/
n27http://linked.opendata.cz/resource/drugbank/drug/DB00305/identifier/kegg-drug/
n28http://linked.opendata.cz/resource/drugbank/drug/DB00305/identifier/drugbank/
n6http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n16http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00305/identifier/national-drug-code-directory/
n10http://www.drugs.com/cdi/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n20http://linked.opendata.cz/resource/drugbank/drug/DB00305/identifier/chemspider/
n13http://linked.opendata.cz/resource/atc/
n7http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00305
rdf:type
n3:Drug
n3:description
An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional alkylating agents causing cross-linking of DNA and inhibition of DNA synthesis. [PubChem]
n3:dosage
n29:271B4EF5-363D-11E5-9242-09173F13E4C5 n29:271B4EF6-363D-11E5-9242-09173F13E4C5 n29:271B4EF7-363D-11E5-9242-09173F13E4C5 n29:271B4EF8-363D-11E5-9242-09173F13E4C5 n29:271B4EF9-363D-11E5-9242-09173F13E4C5 n29:271B4EFA-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
8-48 min
n3:indication
For treatment of malignant neoplasm of lip, oral cavity, pharynx, digestive organs, peritoneum, female breast, and urinary bladder. Also used as an adjunct to ab externo glaucoma surgery.
n3:manufacturer
n11:271B4EE8-363D-11E5-9242-09173F13E4C5 n11:271B4EED-363D-11E5-9242-09173F13E4C5 n11:271B4EEE-363D-11E5-9242-09173F13E4C5 n11:271B4EEB-363D-11E5-9242-09173F13E4C5 n11:271B4EEC-363D-11E5-9242-09173F13E4C5 n11:271B4EE9-363D-11E5-9242-09173F13E4C5 n11:271B4EEA-363D-11E5-9242-09173F13E4C5
owl:sameAs
n6:DB00305 n21:DB00305
dcterms:title
Mitomycin
adms:identifier
n15:Mitomycin n19:27504 n20:5544 n22:5746 n23:46508353 n24:55390-451-01 n25:PA450524 n26:C06681 n27:D00208 n28:DB00305
n3:mechanismOfAction
Mitomycin is activated in vivo to a bifunctional and trifunctional alkylating agent. Binding to DNA leads to cross-linking and inhibition of DNA synthesis and function. Mitomycin is cell cycle phase-nonspecific.
n3:packager
n11:271B4EE3-363D-11E5-9242-09173F13E4C5 n11:271B4EE4-363D-11E5-9242-09173F13E4C5 n11:271B4EE1-363D-11E5-9242-09173F13E4C5 n11:271B4EE2-363D-11E5-9242-09173F13E4C5 n11:271B4EE7-363D-11E5-9242-09173F13E4C5 n11:271B4EE5-363D-11E5-9242-09173F13E4C5 n11:271B4EE6-363D-11E5-9242-09173F13E4C5 n11:271B4EE0-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
Approximately 10% of a dose of mitomycin is excreted unchanged in the urine.
n3:synonym
Mitamycin Mitomycin Mitomycin C 7-Amino-9alpha-methoxymitosane Ametycine Mitocin-C MMC Mutamycin
n3:toxicity
Oral, mouse: LD<sub>50</sub> = 23 mg/kg; Oral, rat: LD<sub>50</sub> = 30 mg/kg. Symptoms of overdose include nausea and vomiting.
n7:hasAHFSCode
n8:10-00-00
n3:synthesisReference
Leslie Jimenez, Zheng Wang, "Synthesis of mitomycin and its analogs." U.S. Patent US5523411, issued June, 1972.
n16:hasConcept
n17:M0013948
foaf:page
n10:mitomycin.html n18:mitomycin.htm
n3:IUPAC-Name
n4:271B4EFF-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4F05-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4F04-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4F01-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4F02-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4F03-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4F15-363D-11E5-9242-09173F13E4C5 n4:271B4EFD-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4F18-363D-11E5-9242-09173F13E4C5 n4:271B4EFB-363D-11E5-9242-09173F13E4C5 n4:271B4EFE-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4EFC-363D-11E5-9242-09173F13E4C5
n3:pKa
n4:271B4F19-363D-11E5-9242-09173F13E4C5
n7:hasATCCode
n13:L01DC03
n3:H-Bond-Acceptor-Count
n4:271B4F0B-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4F0C-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4F06-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4F07-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4F09-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4F08-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4F0A-363D-11E5-9242-09173F13E4C5
n3:absorption
Erratic.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
50-07-7
n3:category
n3:containedIn
n12:271B4EF4-363D-11E5-9242-09173F13E4C5 n12:271B4EEF-363D-11E5-9242-09173F13E4C5 n12:271B4EF2-363D-11E5-9242-09173F13E4C5 n12:271B4EF3-363D-11E5-9242-09173F13E4C5 n12:271B4EF0-363D-11E5-9242-09173F13E4C5 n12:271B4EF1-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B4F11-363D-11E5-9242-09173F13E4C5
n3:Boiling-Point
n4:271B4F17-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4F13-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4F14-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B4F16-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4F10-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4F0F-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4F12-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4F00-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4F0D-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4F0E-363D-11E5-9242-09173F13E4C5